PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Net Current Asset Value 2 year CAGR for the Trailing 12 Months (TTM) ending March 31, 2024: 56.54%

PureTech Health PLC Net Current Asset Value 2 year CAGR is 56.54% for the Trailing 12 Months (TTM) ending March 31, 2024. Net current asset value is a financial metric that represents the excess of a company's current assets over its total liabilities. It is calculated by subtracting the total liabilities from the total current assets of a company. Net current asset value provides insights into the value that would be available to shareholders if the company were to liquidate its current assets and pay off its liabilities. This metric is used to assess the company's liquidity position and the potential value for shareholders in a liquidation scenario. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

PureTech Health PLC Net Current Asset Value for the Trailing 12 Months (TTM) ending September 30, 2022 was 138,194,000.00, a 52.80% change year over year.
PureTech Health PLC Net Current Asset Value for the Trailing 12 Months (TTM) ending September 30, 2021 was 90,444,000.00, a 259.08% change year over year.
PureTech Health PLC Net Current Asset Value for the Trailing 12 Months (TTM) ending September 30, 2020 was -56,854,000.00.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends